Haemato Ag

HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of highpriced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures on the HAEMATO AG share.

Haemato ag. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures of the HAEMATO AG share Subscribed capital EUR 22,867,154 Listed class of shares Bearer ordinary shares ISIN DE WKN Stock exchange code HAE Contact HAEMATO AG, Investor Relations Telefon 49 (0)30 7 30 86 70 ir@haematoag. Telefon 0800 293 527 Telefax 0800 296 426 service@haematoat. HAEMATO AG / Key word(s) Takeover/Capital IncreaseHAEMATO AG HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG Contribution of the company within the scope of a capital increase in kind of HAEMATO AG15Dec / 1500 CET/CESTDisclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AGThe issuer.

About HAEMATO HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of highpriced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures on the HAEMATO AG share. View the latest HAEMATO AG (HAEK) stock price, news, historical charts, analyst ratings and financial information from WSJ. DGAPNews HAEMATO AG / Key word(s) Takeover/Capital Increase 1512 / 1510 The issuer is solely responsible for the content of this announcement Berlin, 1512 M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital.

Besides the distribution of generic drugs HAEMATO imports drugs from the European Economic Area (EEA) These find their way to patients in Germany in two different ways either as parallel imports or as reimports In any case, the products of the importers are always original preparations. HAEMATO AG / Key word(s) PersonnelHAEMATO AG Expansion of the board of directors Strengthening the strategic and operative implementation of the product business in the Haemato Group 30Nov / 1500 CET/CESTDisclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AGThe issuer is solely responsible for. HAEMATO AG Haemato AG engages in the pharmaceutical industry It focuses on growth markets of patentfree, and patented medicinal products in the insurancefinanced market Its portfolio include.

HAEMATO AG Haemato AG engages in the pharmaceutical industry It focuses on growth markets of patentfree, and patented medicinal products in the insurancefinanced market Its portfolio include. M1 Kliniken AG announces that as of today Mr Patrick Brenske will join the Management Board of HAEMATO AG At the same time, Mr Brenske will resign from the ManagementBoard of M1 Kliniken AG, with Dr Walter von Horstig from now on acting as sole member of the Management Board Mr Brenske will continue to advise M1. Find out the direct holders, institutional holders and mutual fund holders for HAEMATO AG ON (HAEDE).

HAEMATO AG, founded in 1993, is a pharmaceutical company The focus of its business activities is on the growth markets of highpriced specialty pharmaceuticals The focus is on therapies for cancer, HIV and other chronic diseases. DGAPNews HAEMATO AG / Key word(s) Takeover/Capital Increase1512 / 1510 The issuer is solely responsible for the content of this announcementBerlin, 1512 M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital. HAEMATO AG The sales of HAEMATO AG increased in the first nine months of by 238 % compared to the same period of the previous year to 1756 million EUR EQ Summary.

Haemato AG is a pharmaceutical company The Company's business activities focus on generic and EU import drugs. If you would like to report side effects to HAEMATO PHARM GmbH medicines, please contact the Quality Department quality@haematode In case of medical emergencies, patients should contact their doctor and/or medical emergency service immediately. HAEMATO AG The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, Mr Zimdars is currently Executive Board Member of HAEMATO AG and Supervisory Board Member of M1 Kliniken AG.

HAEMATO PHARM has set itself the goal of making an active contribution to reducing costs in the German healthcare system The pharmaceutical company is committed to providing optimum care for chronically ill people Since 05, pharmacists and patients have been receiving highquality generics as well as parallel and reimports from HAEMATO. DGAPNews HAEMATO AG / Key word(s) Quarter Results/9 Month figures2311 / 1615 The issuer is solely responsible for the content of this announcementNovember 23, The sales of HAEMATO AG increased in the first nine months of by 238 % compared to the same period of the previous year to 1756 million EURHAEMATO AG, Berlin (ISIN DE000VV1), achieved IFRS group sales of EUR. Haemato AG is a pharmaceutical company The Company's business activities focus on generic and EU import drugs.

To keep it practical, we’ll show how HAEMATO AG’s P/E ratio could help you assess the value on offer HAEMATO has a P/E ratio of 1118 , based on the last twelve months That corresponds to an. About HAEMATO HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of highpriced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures on the HAEMATO AG share. HAEMATO AG / Key word(s) Takeover/Capital Increase HAEMATO AG HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG Contribution of the company within the scope of a capital increase in kind of HAEMATO AG 15Dec / 1500 CET/CEST Disclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AG.

Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support. HAEMATO AG / Key word(s) PersonnelHAEMATO AG Expansion of the board of directors Strengthening the strategic and operative implementation of the product business in the Haemato Group 30Nov / 1500 CET/CESTDisclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AGThe issuer is solely responsible for. HAEMATO PHARM has set itself the goal of making an active contribution to reducing costs in the German healthcare system The pharmaceutical company is committed to providing optimum care for chronically ill people Since 05, pharmacists and patients have been receiving highquality generics as well as parallel and reimports from HAEMATO.

About HAEMATO HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of highpriced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures on the HAEMATO AG share. HAEMATO AG is a pharmaceutical company whose focus lies on the growth markets of patent free and patent protected medicinal products With its offer of generics, parallel and reimports especially for the therapies of cancer, HIV and other chronic diseases, HAEMATO contributes actively towards cutting costs in the German healthcare system. Investing in stocks, such as HAEMATO AG, is an excellent way to grow wealth For longterm investors, stocks are a good investment even during periods of the market volatility a stock market downturn means that many stocks are on sale.

HAEMATO AG 0VZ7 Overview Search stock, chart, recent trades, company information, trading information, company news, fundamentals. About HAEMATO HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of highpriced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures on the HAEMATO AG share. Haemato AG engages in the pharmaceutical industry It focuses on growth markets of patentfree, and patented medicinal products in the insurancefinanced market Its portfolio include therapies.

HAEMATO AG / Key word(s) Dividend HAEMATO AG appropriation of profits 21Apr / 18 CET/CEST Disclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AG The issuer is solely responsible for the content of this announcement. DGAPNews HAEMATO AG / Key word(s) Quarter Results/9 Month figures2311 / 1615 The issuer is solely responsible for the content of this announcementNovember 23, The sales of HAEMATO AG increased in the first nine months of by 238 % compared to the same period of the previous year to 1756 million EURHAEMATO AG, Berlin (ISIN DE000VV1), achieved IFRS group sales of EUR. Haemato AG, previously Windsor AG, is a Germanybased pharmaceutical company The Company trades and patentfree and patentprotected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases.

HAEMATO AG, founded in 1993, is a pharmaceutical company The business specialises on the growing markets of highpriced specialty pharmaceuticals The main focus is on therapies for cancer, HIV and other chronic diseases. HAEMATO AG balance sheet, income statement, cash flow, earnings & estimates, ratio and margins View HAEXE financial statements in full. HAEMATO PHARM has been supplying European countries with top original drugs at a particularly favourable price for ten years now This philosophy is supported both by the production of our own products and the import of original European medicines.

HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of highend specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases In addition, the inhouse development of innovative medical devices for the beauty market was started. View the latest HAEMATO AG (HAEK) stock price, news, historical charts, analyst ratings and financial information from WSJ. HAEMATO AG / Key word(s) Takeover/Capital Increase HAEMATO AG HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG Contribution of the company within the scope of a capital increase in kind of HAEMATO AG 15Dec / 1500 CET/CEST Disclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AG.

HAEMATO AG 0VZ7 Trade recap Search stock, chart, recent trades, company information, trading information, company news, fundamentals. HAEMATO AG, founded in 1993, is a pharmaceutical company The business specialises on the growing markets of highpriced specialty pharmaceuticals The main focus is on therapies for cancer, HIV and other chronic diseases. DGAPNews HAEMATO AG / Key word(s) Interim Report/Half Year Results HAEMATO AG Interim Report 19 / 1643 The issuer is sol.

The new HAEMATO shares were issued at a reference price of €2355 per share, which corresponds to the volumeweighted average price of HAEMATO AG in the Xetra trading system in the period from 2711 to 912. Haemato AG, previously Windsor AG, is a Germanybased pharmaceutical company The Company trades and patentfree and patentprotected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. Besides the distribution of generic drugs HAEMATO imports drugs from the European Economic Area (EEA) These find their way to patients in Germany in two different ways either as parallel imports or as reimports In any case, the products of the importers are always original preparations.

HAEMATO AG / Key word(s) PersonnelHAEMATO AG Expansion of the board of directors Strengthening the strategic and operative implementation of the product business in the Haemato Group 30Nov / 1500 CET/CESTDisclosure of an inside information acc to Article 17 MAR of the Regulation (EU) No 596/14, transmitted by DGAP a service of EQS Group AGThe issuer is solely responsible for. HAEMATO AG, founded in 1993, is a pharmaceutical company The focus of its business activities is on the growth markets of highpriced specialty pharmaceuticals The focus is on therapies for cancer, HIV and other chronic diseases. DGAPNews HAEMATO AG / Key word(s) Quarter Results/9 Month figures2311 / 1615 The issuer is solely responsible for the content of this announcementNovember 23, The sales of HAEMATO AG increased in the first nine months of by 238 % compared to the same period of the previous year to 1756 million EURHAEMATO AG, Berlin (ISIN DE000VV1), achieved IFRS group sales of EUR.

HAEMATO AG does not provide for refunds of charges The price determination for the 2,286,715 converted shares resulting from the capital reduction with the new ISIN DE000VV1 in the open market on the Frankfurt Stock Exchange will commence on September 2, Existing stock market orders expire at the end of September 1,. Haemato AG engages in the pharmaceutical industry It focuses on growth markets of patentfree, and patented medicinal products in the insurancefinanced market Its portfolio include therapies for. HAEMATO AG (), is not the largest company out there, but it led the XTRA gainers with a relatively large price hike in the past couple of weeksAs a small cap stock, which tends to lack high analyst coverage, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value.

Haemato AG is a pharmaceutical company The Company's business activities focus on generic and EU import drugs Address Lilienthalstrasse 5C Schoenefeld, Germany Phone. HAEMATO AG, founded in 1993, is a pharmaceutical company The business specialises on the growing markets of highpriced specialty pharmaceuticals The main focus is on therapies for cancer, HIV and other chronic diseases. HAEMATO PHARM has been supplying European countries with top original drugs at a particularly favourable price for ten years now This philosophy is supported both by the production of our own products and the import of original European medicines.

Company profile page for HAEMATO AG including stock price, company news, press releases, executives, board members, and contact information. Haemato ag Equity Research, Broker Reports, and media content on HAEMATO AG Access the latest forecasts, broker valuations, multiples, and video content from the city about HAEMATO AG. HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of highpriced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG company facts, information and financial ratios from MarketWatch. HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange Key figures on the HAEMATO AG share Subscribed capital EUR 22,867,154 Listed class of shares bearer ordinary shares ISIN DE WKN Stock exchange code HAE Contact HAEMATO AG, Investor Relations Telefon 49 (0)30 7 30 86 70 ir@haematoag. HAEMATO AG 0VZ7 Overview Search stock, chart, recent trades, company information, trading information, company news, fundamentals.

HAEMATO AG Corporate News HAEMATO AG was able to achieve sales of 1978 mEUR and an EBITDA of 19 mEUR for the fiscal year 19 according to preliminary IFRS financial statements HAEMATO AG, Berlin (ISIN DE), achieved consolidated sales of 1978 mEUR (previous year 2741 mEUR), an operating result (EBIT) of kEUR (previous year.